BOT is going to take its acne treatment BTX1503 forward to a Phase 3 study and start two new studies on rosacea and testing the anti-microbial properties of CBD. The results of the BTX1204 Atopic Dermatitis Study is expected in the current quarter. We maintain our SPEC BUY recommendation and $0.29 price target.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.